EDGAR·FLOW

ASP Isotopes Inc. — Form 10-Q

Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 48/100
What the filing says
ASP Isotopes (lender) increased a term loan facility to Renergen (borrower) from USD 48.6M to USD 120M via Fourth and Fifth Addenda (May–September 2026). Concurrently, Mahlako Gas Energy subscribed for 2,650 A Ordinary Shares in Tetra4 (Renergen subsidiary) for R265M and purchased 2,850 A Ordinary Shares from Renergen for R285M (total transaction R550M ≈ USD 30M), acquiring 5.5% equity stake. Mahlako is funded by Mahlako Energy Fund and Third Way Investment Partners. Transaction includes put option allowing Mahlako to force-sell equity back to Renergen under specified breach/delay events (Phase II construction delay >31 May 2025, environmental appeal upheld, covenant breach, sanctions list involvement).
Why this rating

Loan expansion ($71.4M increment) is ~18% of ASP's $399.8M market cap—material but not transformational. Equity raise ($30M–equivalent) for Renergen subsidiary is routine project financing. Put option creates downside protection for investor but introduces refinancing risk for Renergen if triggered.

View original filing on SEC.gov ↗ ASPI · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.